Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056589 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00056589 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 11 participants.
The verdict
NCT00056589, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This trial was conducted in the United States of America (USA). The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.
Interventions
- DRUG catridecacog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-03 |
| Est. Completion | 2003-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056589
The ClinicalTrials.gov registry entry for NCT00056589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which catridecacog is the first listed.
NCT00056589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056589 about?
NCT00056589 is a clinical study titled "Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency". This trial was conducted in the United States of America (USA). The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.
What is the current status of trial NCT00056589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2003-03. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00056589?
The interventions under investigation include: catridecacog (DRUG).
Who is sponsoring clinical trial NCT00056589?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.